EBV Related PTCL clinical trials at UCSF
1 research study open to eligible people
EBV Related PTCL is a type of cancer. UCSF is looking for participants for a clinical trial called "Nanatinostat in Combination With Valganciclovir" for patients who have relapsed or refractory lymphomas. This trial is testing a combination of drugs to see if it is effective in treating this cancer.
Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
open to eligible people ages 18 years and up
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas
San Francisco, California and other locations